Effects of statins on lipid profile in chronic kidney disease patients: A meta-analysis of randomized controlled trials

Current Medical Research and Opinion

Volumn 29, Issue 5, 2013, Pages 435-451

  Nikolic, Dragana ^a   Nikfar, Shekoufeh ^b,c   Salari, Pooneh ^d   Rizzo, Manfredi ^a,e   Ray, Kausik K ^f   Pencina, Michael J ^g   Mikhailidis, Dimitri P ^h   Toth, Peter P ⁱ   Nicholls, Stephen J ^j   Rysz, Jacek ^k   Abdollahi, Mohammad ^l   Banach, MacIej ^k  

^a UNIVERSITY OF PALERMO   (Italy)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g BOSTON UNIVERSITY   (United States)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ UNIVERSITY OF ILLINOIS   (United States)

^j UNIVERSITY OF ADELAIDE   (Australia)

^k MEDICAL UNIVERSITY OF LODZ   (Poland)

^l TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

Cholesterol; Chronic kidney disease; Dialysis; Hemodialysis; Lipids; Lipoproteins; Meta analysis; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; DATA BASE; DIALYSIS; DRUG EFFECT; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84876207881     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.779237     Document Type: Article

References (69)

1. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007;71:159-66
2. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70
3. Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007;49:776-85
4. Nannayakkara PWB, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007;167:1262-70
5. Rizzo M, Banach M, Montalto G, Mikhailidis DP. Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci 2012;8:598-600
6. Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006;21:337-44
7. Collins AJ, Li S, Ma JS, et al. Cardiovascular disease in end stage renal disease patients. Am J Kidney Dis 2001;38(Suppl 1):S26-9
8. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl 12):S16-23
9. Muntner P, He J, Astor BC, et al. Traditional and non-traditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16: 529-38
10. Ganesh S, Stack A, Levin N, et al. Association of elevated serum PO(4), Ca x PO(4), and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
11. Mallamaci F, Zoccali C, Tripei G, et al CREED Investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002;61:609-14
12. Yu YH, Wang Y, Dong B, et al. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia. Chin Med J 2005;118:621-6
13. Kasiske BL, O'Donnell MP, Schmitz PG, et al. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990;37:880-91
14. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003;14:2084-91
15. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002;39:283-90
16. Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002;39:1213-17
17. Rocco MV, Berns JS. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-86
18. Fellstrom BC, Jardine AG, Schmieder RE, et al AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New Eng J Med 2009;360:1395-407
19. Deng J, Wu Q, Liao Y, et al. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and metaanalysis. Nephrology (Carlton) 2012;17:545-51
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
21. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol 2006;26:82-6
22. Holmberg B, Brannstrom M, Bucht B, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scan J Urol Nephrol 2005;39: 503-10
23. Goicoechea M, Garcia de Vinuesa S, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006;17(12 Suppl 3):S231-5
24. Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005;96:1290-2
25. Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17:1513-17
26. Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein. J Nephrol 2009;22:83-9
27. Walker RJ, Sutherland WHF, Walker HL, et al. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. Nephrol Dial Transplant 1997;12:87-92
28. Mastalerz-Migas A, Reksa D, Pokorski M, et al. Comparison of a statin vs hypolipidemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol 2007;58(Suppl 5):363-70
29. Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50
30. Athyros VG, Hatzitolios AI, Karagiannis A, et al IMPERATIVE Collaborative Group. Improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. The IMPERATIVE renal analysis. Arch Med Sci 2011;7:984-92
31. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 2007;11: 1-14
32. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997;12:1908-15
33. Guijarro C, Keane WF. Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 1993;2:372-9
34. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 2010;11:2665-74
35. Yang WQ, Song NG, Ying SS, et al. Serum lipid concentrations correlate with the progression of chronic renal failure. Clin Lab Sci 1999;12:104-8
36. Takemura T, Yoshioka K, Aya N, et al. Apolipoproteins and lipoprotein-receptors in glomeruli in human kidney diseases. Kidney Int 1993;43:918-27
37. Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low density lipoproteins by mesangial cells. J Am Soc Nephrol 1993;4:187-94
38. Coritsidis G, Rifici V, Gupta S, et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991;39:858-66
39. Quenn MT, Parthasarathy S, Fong LG, Steimberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8
40. Herná ndez-Perera O, Pé rez-Sala D, Navarro-Antolin J, et al. Effects of the 3- hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-19
41. Girona J, La Ville AE, Sola R, et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846-51
42. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63
43. Fathi R, Isbel N, Short L, et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 2004;43:45-52
44. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 2005;45:2-14
45. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J Cardiometab Syndr 2009;4:E4-9
46. Chan PCK, Robinson JD, Yeung WC, et al. Lovastatin in glomerulonephritic patients with hyperlipidemia and heavy proteinuria. Nephrol Dial Transplant 1992;7:93-9
47. Collins R, Armitage J, Parish S, et al Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
48. Shepherd J, Kastelein JJ, Bittner V, et al TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
49. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51: 952-65
50. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96(5A):24-33F
51. Koc M, Dogan C, Arinsoy T, et al. Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodial Int 2011;15:366-73
52. Efstratiadis G, Tziomalos K, Mikhailidis DP, et al. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008;6:93-107
53. Barylski M, Małyszko J, Rysz J, et al. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011;7:1055-66
54. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:251-62
55. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:263-75
56. Wanner C, Krane V, Marz W, et al. for the German Diabetes and Dialysis Study Group. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48
57. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006;26:523-39
58. Nitta K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clin Exp Nephrol 2012;16:522-9
59. Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol 2012;178:100-5
60. Heimburger O. Lipid disorders, statins and the peritoneal membrane. Contrib Nephrol 2009;163:177-82
61. Di Lullo L, Addesse R, Comegna C, et al. Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Adv Ther 2005;22:601-12
62. Dornbrook-Lavender KA, Joy MS, et al. Effects of atorvastatin on lowdensity lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005;25: 335-44
63. Lins RL, Matthys KE, Billiouw JM, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004;62:287-94
64. Fiorini F, Patrone E, Castelluccio A. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients. Clin Ther 1994;145:213-17
65. Sawara Y, Takei T, Uchida K, et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Inter Med 2008;47:1505-10
66. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
67. Baigent C, Landray MJ, Reith C, et al SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
68. Banach M, Nikfar S, Rahimi R, et al. Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects - A meta-analysis of randomized controlled trials. Int J Cardiol 2013; (in press)
69. Mercando AD, Lai HM, Aronow WS, et al. Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci 2012;8:57-62